Business context and reporting period
Oculis Holding AG filed an audited Form 20-F for the fiscal year ended December 31, 2023; it is an annual report, not a standalone 2023 Q4 earnings report. The company is a Switzerland-based, clinical-stage biopharmaceutical business focused on ophthalmic therapies. Its three clinical-stage candidates are OCS-01, OCS-02 (licaminlimab) and OCS-05. Financial statements are prepared under IFRS Accounting Standards, with amounts below in CHF unless noted.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Product sales revenue | None | None |
| Grant income | CHF 0.9m | CHF 0.9m |
| Research and development expense | CHF 29.2m | CHF 22.2m |
| General and administrative expense | CHF 17.5m | CHF 11.1m |
| Merger and listing expense | CHF 34.9m | None |
| Operating loss | CHF 80.7m | CHF 32.4m |
| Net loss | CHF 88.8m | CHF 38.7m |
| Basic and diluted loss per share | CHF 2.97 | CHF 11.32 |
| Net cash used in operating activities | CHF 53.8m | CHF 25.1m |
The company reported no product revenue, so product gross margin and operating margin are not meaningful. FY2023 net loss was CHF 2.97 per share; the FY2022 per-share comparison reflects the business-combination share exchange and is not directly comparable without that context.
At December 31, 2023, cash and cash equivalents were CHF 38.3m and short-term financial assets were CHF 53.3m, totaling CHF 91.7m. Current assets were CHF 101.0m and current liabilities CHF 19.1m. Total assets were CHF 114.4m, shareholders’ equity CHF 93.7m and total liabilities CHF 20.6m. No long-term financial debt remained: CHF 122.4m of preferred-share liabilities at year-end 2022 converted to ordinary shares at the March 2023 business-combination closing. Year-end liabilities included CHF 5.4m of warrant liabilities and CHF 0.6m of lease liabilities.
Cash increased CHF 21.6m during 2023, reflecting CHF 129.7m of financing inflows, partly offset by CHF 53.8m of operating cash use and CHF 54.2m of investing cash use, primarily purchases of short-term financial assets. The 2023 financing included the business combination, PIPE and convertible-loan conversions, the June public offering, and warrant and option exercises.
Material changes versus FY2022
- Net loss more than doubled, with R&D expense up 31.6% as clinical activity expanded and G&A expense up 58.1%, including public-company and transaction-related costs.
- The CHF 34.9m merger and listing charge was a one-time, non-cash expense from accounting for the business combination as a share-based payment for a listing service.
- Finance expense declined to CHF 1.3m from CHF 6.4m because preferred shares converted in March 2023. However, the company recorded a CHF 3.4m warrant fair-value loss and CHF 4.7m foreign-exchange loss in 2023.
- Cash, cash equivalents and short-term financial assets rose from CHF 19.8m to CHF 91.7m after financing. Operating cash use increased, and R&D commitments rose to CHF 50.5m from CHF 13.1m, including CHF 23.6m due within one year.
Outlook, commentary and risks
Management said existing cash, cash equivalents and short-term financial assets were expected to fund operations for at least 12 months from the filing date. The company remains loss-making, expects significant further spending and states that additional capital will be needed to support development and potential commercialization. It has no committed source of additional financing; the runway estimate depends on assumptions that could prove inaccurate.
- Clinical programs: OCS-01’s Stage 1 DIAMOND Phase 3 trial for diabetic macular edema (DME) and OPTIMIZE-1 Phase 3 trial for post-cataract-surgery inflammation and pain met reported endpoints. These results are not assurance of replication or approval. DIAMOND-1 and DIAMOND-2 and OPTIMIZE-2 were initiated; OPTIMIZE-2 topline data were expected in Q4 2024.
- Other pipeline: OCS-02 Phase 2b RELIEF enrollment was completed in February 2024, with topline results expected in Q2 2024; these are post-year-end developments reported in the filing. OCS-05 was being evaluated in a first-in-patient acute optic neuritis study in France, with topline data expected in Q4 2024. Its prior FDA clinical hold and need for additional toxicology work remain important regulatory risks.
- Development and execution risks: No candidate has been approved or commercialized. Clinical outcomes, regulatory decisions, manufacturing scale-up, third-party supply, reimbursement, competition, intellectual-property protection and reliance on licensed rights could delay or prevent development or commercialization.
- Contractual and dilution exposure: Potential milestone payments, if achieved, include up to CHF 81.6m under the Novartis license and CHF 94.3m under the Accure license; no milestones had been reached as of year-end. There were 4,254,138 warrants outstanding at year-end, generally exercisable at $11.50 per share, and the company had substantial equity awards and contingent earnout shares that could dilute shareholders.
- Unusual accounting and control items: A CHF 5.0m foreign-currency translation amount was recycled to the income statement in connection with the planned dissolution of Merger Sub 2. Management reported that disclosure controls and internal control over financial reporting were effective at December 31, 2023 and that a previously identified material weakness had been remediated. The auditor did not provide an internal-control attestation because Oculis is an emerging growth company.
Most important facts for investors to verify
- Review subsequent clinical-trial results and regulatory updates against the filing’s stated expectations, particularly for OCS-01, OCS-02 and OCS-05.
- Reassess cash runway using actual quarterly cash burn, committed trial and manufacturing spending, and any new financing; the filing gives no standalone Q4 financial results.
- Confirm the status and timing of CHF 50.5m in external research commitments and contingent license milestones, and distinguish contractual maximums from amounts currently payable.
- Track fully diluted share exposure, including warrants, options, earnout instruments and future equity issuance.
- Check for updated disclosures on the OCS-05 FDA pathway, manufacturing capacity, licensed intellectual-property rights, and remediation of the prior control weakness.